...A. Thank you, Traci, and thank you all for joining us today on short notice to hear about our agreement to acquire Inozyme Pharma. B. Inozyme's investigational enzyme therapy replacement therapy, INZ-701, is currently being assessed for the treatment of ENPP1 deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. C. Data from an ongoing Phase III pivotal study of INZ-701 in children is expected in early 2026 with potential regulatory approval in 2027. D. INZ-701 for the treatment of ENPP1 deficiency is a strong strategic fit for BioMarin. E. The product profile of INZ-701, a disease-modifying enzyme therapy replacement therapy, aligns with our strengths and core capabilities, advancing medicines that address new therapeutic areas. F. We expect the pivotal ENERGY 3 study with INZ-701 in children will read out in early 2026 followed by the potential approval in 2027....
